A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab - PubMed (original) (raw)
Clinical Trial
A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab
Aruna Mani et al. Breast Cancer Res Treat. 2009 Sep.
Abstract
Trastuzumab mediates the lysis of HER2-expressing breast cancer cell lines by interleukin-2 (IL-2) primed natural killer (NK) cells. We hypothesized that IL-2 would augment the anti-tumor effects of trastuzumab in MBC in patients who had progressed on or within 12 months of receiving a trastuzumab-containing regimen. Secondary objectives were to measure antibody-directed cellular cytotoxicity (ADCC) against HER2 over-expressing target cells, and to measure serum cytokines. Patients received trastuzumab (4 mg/kg intravenously (IV)) every 2 weeks in combination with daily low-dose IL-2 (1 million IU/m(2) subcutaneously (SC)) and pulsed intermediate-dose IL-2 (12 million IU/m(2) SC). Samples were analyzed for NK cell expansion and ADCC against a HER2-positive breast cancer cell line. In addition, interferon-gamma (IFN-gamma), mRNA expression in peripheral blood mononuclear cells (PBMC) and the following serum cytokines were measured: IFN-gamma, monokine-induced by IFN-gamma (MIG), and interferon-inducible protein ten (IP-10). The median number of treatment cycles was four (range 1-23) and the treatment was well tolerated. There were no objective responses. NK cells were not expanded and ADCC was not enhanced. Eight (62%) patients had a twofold or higher increase in mRNA transcript for IFN-gamma, two (15%) patients had elevated serum levels of IFN-gamma and 12 (92%) had increases angiogenic MIG and IP-10. In trastuzumab-refractory patients adding IL-2 did not produce responses and did not result in NK cell expansion. However, these patients had the ability to respond to IL-2 as evidenced by increases in IFN-gamma transcripts and chemokines. The lack of NK cell expansion may explain the absence of clinical benefit.
Figures
Fig. 1
Treatment schema
Fig. 2
ADCC by patient PBMCs against trastuzumab-coated SKBR3 tumor cells was measured pre- and post-IL-2 treatment. ADCC values were calculated as the percent lysis of trastuzumab-coated SKBR3 tumor cells after subtraction of lysis of these cells in the absence of trastuzumab. ADCC was not significant in any patient
Fig. 3
Serum IFN-γ was measured at the indicated time points (C cycle; D day). Represented here are the only three patients in whom there was detectable IFN-γ. Results were normalized against a _β_-actin internal control
Fig. 4
IFN-γ transcripts were measured by RT-PCR both pre- and post-IL-2 treatment, and are displayed here as fold increase. Transcripts increased in eight patients after IL-2 treatment
Fig. 5
a Serum levels of MIG and b IP-10 were measured at various time points. Shown here are the baseline and peak levels
Similar articles
- A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients.
Parihar R, Nadella P, Lewis A, Jensen R, De Hoff C, Dierksheide JE, VanBuskirk AM, Magro CM, Young DC, Shapiro CL, Carson WE 3rd. Parihar R, et al. Clin Cancer Res. 2004 Aug 1;10(15):5027-37. doi: 10.1158/1078-0432.CCR-04-0265. Clin Cancer Res. 2004. PMID: 15297404 Clinical Trial. - A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies.
Bekaii-Saab TS, Roda JM, Guenterberg KD, Ramaswamy B, Young DC, Ferketich AK, Lamb TA, Grever MR, Shapiro CL, Carson WE 3rd. Bekaii-Saab TS, et al. Mol Cancer Ther. 2009 Nov;8(11):2983-91. doi: 10.1158/1535-7163.MCT-09-0820. Epub 2009 Nov 3. Mol Cancer Ther. 2009. PMID: 19887543 Free PMC article. Clinical Trial. - TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy.
Lu H, Yang Y, Gad E, Inatsuka C, Wenner CA, Disis ML, Standish LJ. Lu H, et al. Clin Cancer Res. 2011 Nov 1;17(21):6742-53. doi: 10.1158/1078-0432.CCR-11-1142. Epub 2011 Sep 14. Clin Cancer Res. 2011. PMID: 21918170 Free PMC article. - Focusing on NK cells and ADCC: A promising immunotherapy approach in targeted therapy for HER2-positive breast cancer.
Li F, Liu S. Li F, et al. Front Immunol. 2022 Dec 19;13:1083462. doi: 10.3389/fimmu.2022.1083462. eCollection 2022. Front Immunol. 2022. PMID: 36601109 Free PMC article. Review. - Combinations of anticancer drugs and immunotherapy.
Mitchell MS. Mitchell MS. Cancer Immunol Immunother. 2003 Nov;52(11):686-92. doi: 10.1007/s00262-003-0427-2. Epub 2003 Aug 26. Cancer Immunol Immunother. 2003. PMID: 12942200 Free PMC article. Review.
Cited by
- Breast cancer immunotherapy: a comprehensive review.
Keshavarz S, Wall JR, Keshavarz S, Vojoudi E, Jafari-Shakib R. Keshavarz S, et al. Clin Exp Med. 2023 Dec;23(8):4431-4447. doi: 10.1007/s10238-023-01177-z. Epub 2023 Sep 1. Clin Exp Med. 2023. PMID: 37658246 Review. - Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+ breast tumors.
Rivas EI, Linares J, Zwick M, Gómez-Llonin A, Guiu M, Labernadie A, Badia-Ramentol J, Lladó A, Bardia L, Pérez-Núñez I, Martínez-Ciarpaglini C, Tarazona N, Sallent-Aragay A, Garrido M, Celià-Terrassa T, Burgués O, Gomis RR, Albanell J, Calon A. Rivas EI, et al. Nat Commun. 2022 Sep 9;13(1):5310. doi: 10.1038/s41467-022-32782-3. Nat Commun. 2022. PMID: 36085201 Free PMC article. - Intratumoral delivery of dendritic cells plus anti-HER2 therapy triggers both robust systemic antitumor immunity and complete regression in HER2 mammary carcinoma.
Ramamoorthi G, Kodumudi K, Snyder C, Grover P, Zhang H, Greene MI, Basu A, Gallen C, Wiener D, Costa RLB, Han HS, Koski G, Czerniecki BJ. Ramamoorthi G, et al. J Immunother Cancer. 2022 Jun;10(6):e004841. doi: 10.1136/jitc-2022-004841. J Immunother Cancer. 2022. PMID: 35710296 Free PMC article. - Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer.
Nelson MA, Ngamcherdtrakul W, Luoh SW, Yantasee W. Nelson MA, et al. Cancer Metastasis Rev. 2021 Jun;40(2):519-536. doi: 10.1007/s10555-021-09968-0. Epub 2021 May 7. Cancer Metastasis Rev. 2021. PMID: 33963482 Free PMC article. Review. - Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond.
Costa RLB, Czerniecki BJ. Costa RLB, et al. NPJ Breast Cancer. 2020 Mar 12;6:10. doi: 10.1038/s41523-020-0153-3. eCollection 2020. NPJ Breast Cancer. 2020. PMID: 32195333 Free PMC article. Review.
References
- Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792. doi: 10.1056/NEJM 200103153441101. - DOI - PubMed
- Barok M, Isola J, Palyi-Krekk Z, Nagy P, Juhasz I, Vereb G, Kauraniemi P, Kapanen A, Tanner M, Vereb G, Szollosi J. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther. 2007;6:2065–2072. doi: 10.1158/1535-7163.MCT-06-0766. - DOI - PubMed
- Yamaguchi Y, Hironaka K, Okawaki M, Okita R, Matsuura K, Ohshita A, Toge T. HER2-specific cytotoxic activity of lymphokine-activated killer cells in the presence of trastuzumab. Anticancer Res. 2005;25:827–832. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P01 CA95426/CA/NCI NIH HHS/United States
- K24 CA093670-02/CA/NCI NIH HHS/United States
- U01 CA76576-07/CA/NCI NIH HHS/United States
- K24 CA93670-02/CA/NCI NIH HHS/United States
- P30 CA16058-29/CA/NCI NIH HHS/United States
- U01 CA076576/CA/NCI NIH HHS/United States
- P01 CA095426/CA/NCI NIH HHS/United States
- P30 CA016058/CA/NCI NIH HHS/United States
- T32 CA009338/CA/NCI NIH HHS/United States
- 5T32CA009338-28/CA/NCI NIH HHS/United States
- N01 CM-62201/CM/NCI NIH HHS/United States
- N01CM62201/CA/NCI NIH HHS/United States
- K24 CA093670/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous